Delivery Order SPE2DB20D1109-SPE2DB22FN02C
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% Eye Emulsion 30s. The $2,853.54 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% eye emulsion. The $16,124.33 firm fixed-price delivery order is a component of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,537.07 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of November 3, 2021 and was awarded on November 2, 2021. This delivery order is part of a larger $999,999,999 Indefinite...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,023.80 firm fixed-price delivery order (SPE2DB22FN07L) is for the supply of Restasis 0.05% eye emulsion to support military treatment facilities and federal healthcare programs. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,160.96 firm fixed-price delivery order is for Restasis 0.05% eye emulsion, a specialty medication used in the treatment of dry eye disease. The contract has an ultimate completion date of May 2, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,800.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for the company to provide a comprehensive range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,062.04 firm-fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion, a specialty pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November...
- This federal contract award, valued at $5,579.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a specialty pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $4,421.03 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of...
- This federal contract award, valued at $2,645.94, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a prescription eye drop medication. This is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FN02CDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,806.01 Firm Fixed Price Delivery Order contract is for the supply of Restasis 0.05% Eye Emulsion, a prescription medication used to treat dry eye disease. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This order falls under that larger IDC vehicle. The contract did not have any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems, leveraging its extensive supply chain and distribution capabilities to efficiently fulfill government contracts for essential medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 11/4/21 |